Ad
Monday, 24 April 2017
Profit profile helps Lilly shares rebound from Alzheimer's setback
NEW YORK (Reuters) - Shares of Eli Lilly & Co have staged a dramatic rebound following massive disappointment for its experimental Alzheimer's medicine late last year, outperforming rivals as investors warm to the drugmaker's profit outlook.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment